日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study

儿童心脏移植术后第一年新检测到的供体特异性抗HLA抗体的发生率、特征和影响:来自CTOTC-04研究的报告

Dipchand, A I; Webber, S; Mason, K; Feingold, B; Bentlejewski, C; Mahle, W T; Shaddy, R; Canter, C; Blume, E D; Lamour, J; Zuckerman, W; Diop, H; Morrison, Y; Armstrong, B; Ikle, D; Odim, J; Zeevi, A

Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept

经验教训:贝拉西普治疗钙调神经磷酸酶抑制剂和避免使用皮质类固醇的随机试验提前终止

Newell, K A; Mehta, A K; Larsen, C P; Stock, P G; Farris, A B; Mehta, S G; Ikle, D; Armstrong, B; Morrison, Y; Bridges, N; Robien, M; Mannon, R B

Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study.

免疫生物标志物与心脏移植结果的多中心分析:器官移植临床试验-05 研究的结果

Starling R C, Stehlik J, Baran D A, Armstrong B, Stone J R, Ikle D, Morrison Y, Bridges N D, Putheti P, Strom T B, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly K P, Briscoe D M, Heeger P S

Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium

器官移植临床试验联盟内同种异体反应性IFNγ ELISPOT检测的标准化和交叉验证

Ashoor, I; Najafian, N; Korin, Y; Reed, E F; Mohanakumar, T; Ikle, D; Heeger, P S; Lin, M

Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury.

多中心验证尿液 CXCL9 作为肾移植损伤风险分层生物标志物

Hricik D E, Nickerson P, Formica R N, Poggio E D, Rush D, Newell K A, Goebel J, Gibson I W, Fairchild R L, Riggs M, Spain K, Ikle D, Bridges N D, Heeger P S